Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York

Breast Cancer Research and Treatment

Volumn 108, Issue 1, 2008, Pages 93-99

  Gaudet, Mia M ^a,f   Gammon, Marilie D ^a   Bensen, Jeannette T ^a   Sagiv, Sharon K ^a,g   Shantakumar, Sumitra ^a,h   Teitelbaum, Susan L ^b   Eng, Sybil M ^c   Neugut, Alfred I ^d,e   Santella, Regina M ^d  

^a IL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d Columbia University ^*  (United States)

^e National Cancer Institute ^*  (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h GLAXOSMITHKLINE   (United States)

Author keywords

Breast cancer; Epidemiology; PAHs; Smoking; TP53

Indexed keywords

POLYCYCLIC AROMATIC HYDROCARBON;

ADULT; AGED; ALLELE; ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER RISK; CIGARETTE SMOKING; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA ADDUCT; FEMALE; GENE; GENE DELETION; GENE INSERTION; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TP 53 GENE;

BREAST NEOPLASMS; DNA ADDUCTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MIDDLE AGED; NEW YORK; POLYCYCLIC HYDROCARBONS, AROMATIC; POLYMERASE CHAIN REACTION; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 43049116553     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9573-0     Document Type: Article

References (30)

1. Goldman R, Shields PG (1998) Molecular epidemiology of breast cancer. In Vivo 12:43-48
2. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878
3. Bode AM, Dong Z (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4:793-805
4. Lioy PJ, Greenberg A (1990) Factors associated with human exposures to polycyclic aromatic hydrocarbons. Toxicol Ind Health 6:209-223
5. Conway K, Edmiston SN, Cui L, Drouin SS, Pang J, He M, Tse CK, Geradts J, Dressler L, Liu ET, Millikan R, Newman B (2002) Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res 62:1987-1995
6. Li D, Zhang W, Sahin AA, Hittelman WN (1999) DNA adducts in normal tissue adjacent to breast cancer: a review. Cancer Detect Prev 23:454-462
7. Martin FL, Venitt S, Carmichael PL, Crofton-Sleigh C, Stone EM, Cole KJ, Gusterson BA, Grover PL, Phillips DH (1997) DNA damage in breast epithelial cells: detection by the single-cell gel (comet) assay and induction by human mammary lipid extracts. Carcinogenesis 18:2299-2305
8. Terry PD, Rohan TE (2002) Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev 11:953-971
9. Rundle A, Tang D, Hibshoosh H, Estabrook A, Schnabel F, Cao W, Grumet S, Perera FP (2000) The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis 21:1281-1289
10. Gammon MD, Santella RM, Neugut AI, Eng SM, Teitelbaum SL, Paykin A, Levin B, Terry MB, Young TL, Wang LW, Wang Q, Britton JA, Wolff MS, Stellman SD, Hatch M, Kabat GC, Senie R, Garbowski G, Maffeo C, Montalvan P, Berkowitz G, Kemeny M, Citron M, Schnabel F, Schuss A, Hajdu S, Vinceguerra V (2002) Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev 11:677-685
11. Gammon MD, Sagiv SK, Eng SM, Shantakumar S, Gaudet MM, Teitelbaum SL, Britton JA, Terry MB, Wang LW, Wang Q, Stellman SD, Beyea J, Hatch M, Kabat GC, Wolff MS, Levin B, Neugut AI, Santella RM (2004) Polycyclic aromatic hydrocarbon-DNA adducts and breast cancer: a pooled analysis. Arch Environ Health 59:640-649
12. Easton D, Ford D, Peto J (1993) Inherited susceptibility to breast cancer. Cancer Surv 18:95-113
13. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94:681-690
14. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105-112
15. Kraft P, Cox DG, Paynter RA, Hunter D, De Vivo I (2005) Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol 28:261-272
16. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313-1316
17. Weston A, Wolff MS, Morabia A (1998) True extended haplotypes of p53: indicators of breast cancer risk. Cancer Genet Cytogenet 102:153-154
18. Gammon MD, Neugut AI, Santella RM, Teitelbaum SL, Britton JA, Terry MB, Eng SM, Wolff MS, Stellman SD, Kabat GC, Levin B, Bradlow HL, Hatch M, Beyea J, Camann D, Trent M, Senie RT, Garbowski GC, Maffeo C, Montalvan P, Berkowitz GS, Kemeny M, Citron M, Schnabe F, Schuss A, Hajdu S, Vincguerra V, Collman GW, Obrams GI (2002) The Long Island breast cancer study project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat 74:235-254
19. Gammon MD, Eng SM, Teitelbaum SL, Britton JA, Kabat GC, Hatch M, Paykin AB, Neugut AI, Santella RM (2004) Environmental tobacco smoke and breast cancer incidence. Environ Res 96:176-185
20. Santella RM, Grinberg-Funes RA, Young TL, Dickey C, Singh VN, Wang LW, Perera FP (1992) Cigarette smoking related polycyclic aromatic hydrocarbon-DNA adducts in peripheral mononuclear cells. Carcinogenesis 13:2041-2045
21. Hosmer DW, Lemeshow S (1989) Applied Logistic Regression. John Wiley and Sons, Inc, New York
22. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954-1956
23. Sjalander A, Birgander R, Kivela A, Beckman G (1995) p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 45:144-149
24. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Daoud J, Frikha M, Jlidi R, Gargouri A (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Annal NY Acad Sci 1010:764-770
25. Pietsch EC, Humbey O, Murphy ME (2006) Polymorphisms in the p53 pathway. Oncogene 25:1602-1611
26. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10:307-311
27. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365
28. Epstein MP, Satten GA (2003) Inference on haplotype effects in case-control studies using unphased genotype data. Am J Hum Genet 73:1316-1329
29. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Borresen-Dale AL (2002) The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11:1684-1688
30. Bhatti P, Sigurdson AJ, Wang SS, Chen J, Rothman N, Hartge P, Bergen AW, Landi MT (2005) Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol Biomarkers Prev 14:2449-2453